Press Inquiries

Renée Hockaday
Director, Communications
Pulmonary Hypertension Association
Office: 301-565-3004 x774 or 240-485-0774

Media Coverage

The Early Diagnosis Campaign Press Room

PHA works to connect media professionals with up-to-date information on pulmonary hypertension. We can also connect members of the press with PH patients and medical leaders in the field of PH.

Press Releases

Dec. 22, 2013 - New Pulmonary Hypertension Drug Approved!
The U.S. Food and Drug Administration (FDA) approved United Therapeutics' oral treprostinil, an extended-release tablet commercially known as Orenitram, for the treatment of pulmonary arterial hypertension (PAH). Orenitram is the first orally administered prostacyclin analogue approved by the FDA for any disease. Read full press release

Oct. 10, 2013 - FDA Approves Tenth Drug for One Rare Disease Affecting Just 20-30,000 Patients: Pulmonary Hypertension Association Highlights Factors Contributing to Rapid Progress
The US Food and Drug Administration this week approved the tenth treatment, riociguat, for pulmonary hypertension (PH), a rare and life-threatening lung disease affecting roughly 20,000-30,000 patients, continuing the remarkable pace of recent progress that distinguishes PH from all but a handful of the 7,000 other rare diseases in this country. An eleventh PH drug will be considered by the FDA later this month. Read full press release

Oct. 3, 2013 - Consensus Guidelines Published on Screening for PAH in Systemic Sclerosis; Recommendations Aim For Earlier Diagnosis of This Leading Cause of Mortality
All patients with systemic sclerosis (SSc) and connective tissue diseases should be screened for pulmonary arterial hypertension (PAH), an international panel of experts recommended in an article published in the September issue of the journal Arthritis & Rheumatism.  The recommendations, part of a larger effort to improve patient outcomes by diagnosing earlier, identify specific tests to be performed in screening these patients for PAH.  Read full press release

May 8, 2013 - 30 Years of Orphan Drug Act, Combined with Science and Advocacy, Reflect Dramatic Progress in a Rare Lung Disease
Pulmonary hypertension (PH), a rare and life-threatening lung disease, has gone from rapidly fatal to treatable with nine drugs developed in just the past 20 years, a phenomenal record for a rare condition. Growth in the understanding and treatment of PH reflects the dramatic progress possible since the passage of the Orphan Drug Act 30 years ago, according to the Pulmonary Hypertension Association (PHA), Read full press release

Resources For Reporting on the Impact of the 1983 Orphan Drug Act (PDF)

April 19, 2013 - Pulmonary Hypertension Association Campaigns to End Misdiagnosis of Now Treatable Lung Disease; Philly Patient's April 27 Gala Reflects Impact on Young Mother's Life
Misdiagnosis of life-threatening pulmonary hypertension (PH) didn’t matter much 20 years ago, when no treatment existed. But nine treatments now can help patients live longer and better -- if enough medical professionals know how to differentiate PH from widespread illnesses with similar symptoms such as asthma, COPD and sleep apnea. Read full press release

June 21, 2012 - Early Diagnosis Campaign Launched for Pulmonary Hypertension
Despite rapid progress in treatment for pulmonary hypertension (PH), an incurable lung disease, repeated misdiagnosis causes many patients to receive care only at advanced stages of the illness. In response, the Pulmonary Hypertension Association today launched an early diagnosis campaign to educate healthcare professionals to spot this disease and to refer patients earlier to specialty PH care. Read full press release

Other PHA Press Releases

Press Kit

Understanding Pulmonary Hypertension

Join our Press List

Media Coverage


The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

© 2015 Pulmonary Hypertension Association. All Rights Reserved.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
    Privacy Policy   Terms of Use    Provide Feedback & Report Bugs


The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.